Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 12/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588903 | 0.83 | TBXA2R (0.41) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL4552217 | 0.82 | TBXA2R (0.48) | TBXA2RAGTR1AGTR2CPT1A | |
| SCHEMBL4376876 | 0.69 | MEN1 (0.44) | TBXA2R | |
| SCHEMBL4385302 | 0.67 | TBXA2R (0.46) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL20593183 | 0.64 | TBXA2R (0.37) | TBXA2R | |
| SCHEMBL9847736 | 0.64 | AGTR1 (0.53) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL6126109 | 0.63 | TSHR (0.48) | — | |
| SCHEMBL5107769 | 0.62 | TBXA2R (0.48) | TBXA2R | |
| SCHEMBL6738367 | 0.62 | AGTR1 (0.40) | TBXA2RAGTR1AGTR2 | |
| SCHEMBL4552025 | 0.61 | KMT2A (0.40) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | TBXA2R 328/4885AGTR1 568/4885AGTR2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.